I-Acute Lymphoblastic Leukemia (T-ALL)-08

UYesheng waseFujian uthe, "Ukuba bendisazi ngeCAR-T kwiBIOOCUS Medical Group, ngendifike kwangethuba."

NgoSeptemba ka-2017, uYesheng waba nerhashalala ebusweni, eyathi yasasazeka kancinci kancinci yaza yadibana namabala. Ngomhla wama-28 kuFebruwari ka-2018, uvavanyo lwe-bone marrow lwaqinisekisa ukuba kukho "i-acute T-cell lymphoblastic leukemia" emva kwezifundo ezininzi ze-chemotherapy, kunye nokuhlolwa okungalunganga okwethutyana. Onke amayeza ayekiswa ngoJuni ka-2019.

NgoMeyi 2021, uYesheng wabonakala eneentlungu ezininzi kwindawo yomlomo kunye nentamo ekhulisiweyo. Ukuhlolwa kwakhona komongo wethambo kuqinisekisile ukuphinda ngokupheleleyo kwe-leukemia. Ngomhla wama-28 kuMeyi, uYesheng wadluliselwa kwiCandelo lesibini leHematology ukuze amkelwe. Emva kokuhlolwa okubanzi, ukuxilongwa kwahlaziywa kwaba "yi-acute leukemia (T/myeloid biphenotypic)."

Umjikelo omnye we-chemotherapy awuzange ubangele ukuxolelwa kwi-bone mongo. Ngomhla wama-27 kuJulayi, uYesheng wafumana i-CD7 CAR-T cell infusion, yalandelwa yi-chemotherapy edityaniswe ne-autologous CD7 CAR-T cell therapy. Emva kweentsuku ezilishumi elinesihlanu emva kokufakwa, uvavanyo lwe-bone mongo lwabonisa isifo esishiyekileyo, kunye ne-grade 1 cytokine release syndrome (CRS) reaction kwaye akukho ziphumo zimbi kwinkqubo ye-nervous central.